

Eduardo Vilar Gomez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7868026/publications.pdf>

Version: 2024-02-01

58
papers

4,009
citations

279798

23
h-index

168389

53
g-index

61
all docs

61
docs citations

61
times ranked

4856
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 115-124.e7.	4.4	25
2	Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. <i>Hepatology</i> , 2022, 75, 968-982.	7.3	3
3	High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. <i>Hepatology</i> , 2022, 75, 1491-1506.	7.3	99
4	PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features. <i>Hepatology</i> , 2022, 76, 1482-1494.	7.3	9
5	REPLY:. <i>Hepatology</i> , 2021, 74, 531-532.	7.3	0
6	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 136-145.e6.	4.4	47
7	Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1292-1293.e3.	4.4	22
8	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , 2021, 73, 2238-2250.	7.3	20
9	Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. <i>Hepatology Communications</i> , 2021, 5, 786-797.	4.3	12
10	Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. <i>Journal of Clinical Lipidology</i> , 2021, 15, 275-291.	1.5	8
11	Racial differences in primary sclerosing cholangitis mortality is associated with community socioeconomic status. <i>Liver International</i> , 2021, 41, 2703-2711.	3.9	6
12	The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00400.	2.5	12
13	Impact of the Association Between PNPLA3 Genetic Variation and Dietary Intake on the Risk of Significant Fibrosis in Patients With NAFLD. <i>American Journal of Gastroenterology</i> , 2021, 116, 994-1006.	0.4	30
14	Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome. <i>Journal of Clinical Lipidology</i> , 2021, 15, 805-813.	1.5	3
15	Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. <i>Hepatology</i> , 2020, 71, 495-509.	7.3	117
16	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	4.4	104
17	Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring. <i>Drug Safety</i> , 2020, 43, 281-290.	3.2	3
18	Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation. <i>BMC Gastroenterology</i> , 2020, 20, 4.	2.0	14

#	ARTICLE	IF	CITATIONS
19	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2020, 19, 674-690.	1.5	72
20	Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. <i>Gastroenterology</i> , 2020, 159, 1985-1987.e4.	1.3	83
21	Extra-hepatic comorbidity burden significantly increases 90-day mortality in patients with cirrhosis and high model for endstage liver disease. <i>BMC Gastroenterology</i> , 2020, 20, 302.	2.0	5
22	Decreased Quality of Life Is Significantly Associated With Body Composition in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2980-2988.e4.	4.4	19
23	Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2305-2314.e12.	4.4	38
24	ADH1B*2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption. <i>Gastroenterology</i> , 2020, 159, 929-943.	1.3	18
25	Comorbidity Burden May Be Associated with Increased Mortality in Patients with Severe Acute Liver Injury Referred for Liver Transplantation. <i>Annals of Transplantation</i> , 2020, 25, e926453.	0.9	1
26	Daily Aspirin Use Reduces Risk of Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease, Providing New Uses for an Old Drug. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2651-2653.	4.4	3
27	Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 836-837.	3.7	0
28	Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 838-839.	3.7	0
29	Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 317-328.	3.7	52
30	Early predictors of outcomes of hospitalization for cirrhosis and assessment of the impact of race and ethnicity at safety-net hospitals. <i>PLoS ONE</i> , 2019, 14, e0211811.	2.5	17
31	Reply. <i>Hepatology</i> , 2019, 70, 752-752.	7.3	0
32	Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study. <i>BMJ Open</i> , 2019, 9, e023597.	1.9	38
33	Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden. <i>Hepatology Communications</i> , 2019, 3, 52-62.	4.3	29
34	Older Age and Disease Duration Are Highly Associated with Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1705-1710.	2.3	8
35	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). <i>Guía de práctica clínica. Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.5	71
36	Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. <i>Journal of Hepatology</i> , 2018, 68, 305-315.	3.7	427

#	ARTICLE	IF	CITATIONS
37	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterology</i> & <i>Hepatology</i> (English Edition), 2018, 41, 328-349.	0.1	7
38	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , 2018, 155, 443-457.e17.	1.3	536
39	Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. <i>Liver International</i> , 2017, 37, 1887-1896.	3.9	52
40	Editorial: treating the liver to treat the kidney in non-alcoholic steatohepatitis - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 566-567.	3.7	0
41	Metformin Modifies Glutamine Metabolism in an In Vitro and in Vivo Model of Hepatic Encephalopathy. <i>Journal of Clinical and Experimental Hepatology</i> , 2017, 7, S58-S59.	0.9	1
42	Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 332-344.	3.7	52
43	Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. <i>Hepatology</i> , 2016, 63, 1875-1887.	7.3	50
44	Reply. <i>Hepatology</i> , 2016, 64, 2266-2267.	7.3	0
45	Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis?. <i>Annals of Internal Medicine</i> , 2016, 165, 373.	3.9	3
46	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 31421.	3.3	33
47	Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, 283-290.	0.9	29
48	Reply. <i>Gastroenterology</i> , 2015, 149, 1988-1989.	1.3	2
49	Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2015, 149, 367-378.e5.	1.3	1,592
50	Oxidative Stress in Autoimmune Liver Disease. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2015, , 325-343.	0.4	1
51	Arterial Blood Pressure Is Closely Related to Ascites Development in Compensated HCV-Related Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e95736.	2.5	7
52	The natural history of compensated HCV-related cirrhosis: A prospective long-term study. <i>Journal of Hepatology</i> , 2013, 58, 434-444.	3.7	66
53	Trends in digestive cancer mortality, Cuba 1987-2008. <i>European Journal of Public Health</i> , 2013, 23, 164-170.	0.3	2
54	Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial. <i>BMJ Open</i> , 2011, 1, e000140-e000140.	1.9	10

#	ARTICLE	IF	CITATIONS
55	Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. World Journal of Gastroenterology, 2010, 16, 2638.	3.3	32
56	Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2009, 30, 999-1009.	3.7	93
57	Application of a biochemical and clinical model to predict individual survival in patients with end-stage liver disease. World Journal of Gastroenterology, 2009, 15, 2768.	3.3	10
58	Viusid, a nutritional supplement, in combination with interferon γ -2b and ribavirin in patients with chronic hepatitis C. Liver International, 2007, 27, 247-259.	3.9	11